Company news

Cytokinetics, Incorporated news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Cytokinetics Announces Proposed Private Placement of $550.0 Million of Convertible Senior Notes

September 15, 2025

Cytokinetics Announces Pricing of Upsized $650.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2027 Convertible Notes

September 15, 2025

Cytokinetics Presents New Data Related to Aficamten at the European Society of Cardiology Congress 2025

August 30, 2025

Cytokinetics Announces Primary Results from MAPLE-HCM Presented at the European Society of Cardiology Congress 2025 and Published in The New England Journal Of Medicine

August 29, 2025

Cytokinetics to Participate in September Investor Conferences

August 26, 2025

Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2025

August 24, 2025

Cytokinetics Names Jim Daly to Board of Directors

August 19, 2025

Cytokinetics Reports Second Quarter 2025 Financial Results and Provides Business Update

August 6, 2025

Cytokinetics to Announce Second Quarter Results On August 7, 2025

July 23, 2025

Cytokinetics Announces Call For Proposals For Annual Corporate Giving Program

June 9, 2025

Cytokinetics to Participate in the Jefferies Global Healthcare Conference

May 28, 2025

Cytokinetics Presents Additional Data Related to Aficamten at the European Society of Cardiology Heart Failure 2025 Congress

May 17, 2025

Cytokinetics to Host Symposium on Contemporary Landscapes in Muscle Biology

May 14, 2025

Cytokinetics Announces Positive Topline Results From MAPLE-HCM

May 12, 2025

Cytokinetics Announces Four Upcoming Presentations at the European Society Of Cardiology Heart Failure 2025 Congress

May 7, 2025

Cytokinetics to Hold Annual Meeting of Stockholders

May 6, 2025

Cytokinetics Reports First Quarter 2025 Financial Results and Provides Business Update

May 5, 2025

Cytokinetics Announces New PDUFA Date for Aficamten in Obstructive Hypertrophic Cardiomyopathy

April 30, 2025

Cytokinetics to Participate in May Investor Conferences

April 29, 2025

Cytokinetics to Announce First Quarter Results on May 6, 2025

April 21, 2025

Cytokinetics to Participate in the 24th Annual Needham Virtual Healthcare Conference

March 30, 2025

Cytokinetics Announces Launch of EARTH-HCM, a Public Health Education Tool for the Hypertrophic Cardiomyopathy Community

March 19, 2025

Cytokinetics Announces Five Presentations at the American College of Cardiology Annual Scientific Session & Expo

March 16, 2025

Cytokinetics to Participate in March Investor Conferences

March 2, 2025

Cytokinetics Reports Fourth Quarter 2024 Financial Results and Provides Business Update

February 26, 2025

Cytokinetics to Announce Fourth Quarter Results on February 27, 2025

February 12, 2025

Cytokinetics Names Robert E. Landry to Board of Directors

February 10, 2025

Cytokinetics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

February 4, 2025

Cytokinetics Announces Recipients of Its Seventh Annual Communications Grant Program

January 29, 2025

Cytokinetics Announces Start of AMBER-HFpEF, a Phase 2 Clinical Trial of CK-586 in Patients With Symptomatic Heart Failure With Preserved Ejection Fraction

January 20, 2025

Cytokinetics Announces 2025 Corporate Milestones and Vision 2030

January 12, 2025

Cytokinetics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 5, 2025

Cytokinetics Announces European Medicines Agency Validation of Marketing Authorization Application for Aficamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy

December 22, 2024

Cytokinetics Announces Sanofi Acquired Rights to Develop and Commercialize Aficamten in Greater China

December 19, 2024

Cytokinetics Announces Start of COMET-HF, a Confirmatory Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients with Symptomatic Heart Failure with Severely Reduced Ejection Fraction

December 2, 2024

Cytokinetics to Participate in December Investor Conferences

December 1, 2024

Cytokinetics Announces FDA Acceptance of New Drug Application for Aficamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy

December 1, 2024

Cytokinetics and Bayer Announce Exclusive Licensing Collaboration for Aficamten in Japan

November 18, 2024

Cytokinetics Presents New Data Relating to Aficamten and Hypertrophic Cardiomyopathy at the American Heart Association Scientific Sessions 2024

November 15, 2024

Cytokinetics Presents Additional Data From GALACTIC-HF at the American Heart Association Scientific Sessions 2024

November 15, 2024

Cytokinetics to Participate in the 2024 Jefferies London Healthcare Conference

November 11, 2024

Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-4015089

November 10, 2024

Cytokinetics Reports Third Quarter 2024 Financial Results

November 5, 2024

Cytokinetics Announces Six Upcoming Presentations at the American Heart Association Scientific Sessions 2024

November 4, 2024

Cytokinetics to Announce Third Quarter Results on November 6, 2024

October 22, 2024

Cytokinetics Highlights Progress in Cardiac Myosin Modulation Programs and Global Commercial Launch Readiness at Investor & Analyst Day

October 15, 2024

Cytokinetics to Host Investor & Analyst Day on October 16, 2024

October 1, 2024

Cytokinetics Presents Additional Data From SEQUOIA-HCM at the HFSA Annual Scientific Meeting

September 29, 2024

Cytokinetics Presents Additional Data from SEQUOIA-HCM at the HCMS Scientific Sessions

September 26, 2024

Cytokinetics Announces Call for Proposals for Its Seventh Annual Communications Grant Program

September 23, 2024

← Newer news releases · Older news releases →

Calls

The 5 newest of 23 calls. Every call is listed under its year.

Decks

The 5 newest of 44 decks. Every deck is listed under its year.